Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 6502000 | Elevated granulocyte strontium in inflammatory arthritides is related to the inflammatory | 1984 Dec | Total cellular strontium and calcium were measured by the nuclear microprobe technique. Increased mass fraction of both elements was found in granulocytes isolated from patients with active rheumatoid arthritis and other kinds of inflammatory arthritides. Increased granulocyte calcium but only marginally elevated granulocyte strontium was demonstrated in patients with scleroderma. The granulocyte accumulation of strontium and calcium seems to be linked to the degree of inflammatory activity, because the granulocyte content of both elements was positively correlated to the plasma concentration of acute-phase proteins. Corticosteroid therapy induced a marked reduction of granulocyte strontium but a more modest decrease of granulocyte calcium. The serum levels of strontium and calcium were within the normal ranges in all patients and were not significantly altered by corticosteroids. | |
| 6380899 | Double-blind crossover comparison of piroxicam and indomethacin in rheumatoid arthritis. | 1984 Jun | This 10-week, double-blind, crossover study compared piroxicam (20 mg administered once daily) and indomethacin (25 mg administered three times daily) in patients with rheumatoid arthritis. In the 30 patients evaluated, both drugs produced statistically significant improvement after 4 weeks compared to placebo in all parameters measured with the exception of joint swelling and 10 m walking time. Piroxicam provided greater improvement with respect to the severity of pain, joint tenderness and restoration of motion, and was significantly more effective than indomethacin in reducing the consumption of paracetamol and in improving morning stiffness. Both drugs were equally effective in improving the remaining parameters measured. Roughly, two-thirds of the patients considered piroxicam to be the more effective agent. With both drugs side effects were mild and infrequent. | |
| 6383228 | Antibodies to dsDNA in connective tissue diseases measured by ultramicro enzyme-linked imm | 1984 | Human sera (171 samples of patients with connective tissue diseases (CTD) were screened for anti-dsDNA antibodies by ultramicro ELISA adapted to the chamber analytical technique (CAT). The assay offers sensitivity superior to the Crithidia luciliae immunofluorescence technique (CLIFT). Positive results are not restricted to systemic lupus erythematosus (SLE). Nine sera of other CTD patients exhibited antibodies to dsDNA as well. This might be a symptom of a relatively slight immunodisturbance with presence of low-avidity antibodies. | |
| 6828587 | Restoration of extensor pollicis longus function by tendon transfer. | 1983 Apr | Transfer of the extensor indicis proprius was carried out in 28 patients with chronic loss of the extensor pollicis longus. The patients were evaluated after intervals ranging from 4 months to 5 years, and 23 (82 percent) showed excellent recovery of long thumb extensor function, although 9 of these did lose as much as 30 degrees of flexion at the interphalangeal joint. There were two failures (7 percent), and two patients were lost to follow-up. One patient ruptured the juncture of the transfer but responded well to reattachment. There were not complications attributed to removal of this tendon from the index finger. | |
| 6755728 | Mixed connective tissue disease: an overview. | 1982 Nov | Mixed connective tissue disease is characterized by overlapping features of classic connective tissue diseases and the presence of antibodies to ribonucleoprotein. Placement of this disorder among the classic disorders still remains controversial. The clinical features, prognosis, and therapeutic features of this syndrome are discussed in this report. | |
| 807223 | [Long-term therapy of progressive chronic polyarthritis with naproxen]. | 1975 Feb | The efficacy of d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) in the treatment of patients with rheumatoid arthritis as well as its good tolerance has been established in double-blind studies which have been conducted in 34 centers in the U.S.A. Since the value of a new antirheumatic drug can only be assessed after years of clinical experience, provision was made in the protocols of the double-blind studies that the patients completing the controlled studies could continue naproxen treatment. Our experience is based on 603 patients, of whom 337 came from controlled, and 266 from previous open studies. The longest treatment with naproxen lasted four years. 16% of the patients discontinued therapy because of a exacerbation of their symptoms, and 8% because of side-effects, the latter being described in detail. Follow-up examinations of the patients were performed 4841 times at bi-monthly intervals. The statistical analysis of the objective disease symptoms showed a significant decrease of the rheumatic manifestations. In order to exclude the possibility of a long-term placebo effect, and as a proof of continuing efficacy, 73 patients received double-blind placebo instead of naproxen (placebo pulse) for two weeks, whereas the others continued on naproxen. Statistical analysis of the objective symptoms during the two treatment phases of the study showed naproxen significantly superior to placebo in all disease manifestations. Symptoms of those patients receiving placebo aggravated rapidly. They improved again after naproxen was resumed. The situation was reverse in those patients who received placebo during the second phase of the study. Side-effects were observed 13 times under placebo, but only two times under naproxen. The integration of a 2-week-placebo-pulse during long-term naproxen therapy of patients with rheumatoid arthritis is a sensitive method to prove the continuing therapeutic efficacy of this drug. | |
| 6860375 | Decreased complement mediated binding of antibody/3H-dsDNA immune complexes to the red blo | 1983 Jun | The complement mediated binding of prepared antibody/3H-dsDNA immune complexes to the red blood cells obtained from a number of patient populations has been investigated. Patients with solid tumors have binding activity similar to that seen in a normal group of individuals. However, a significant fraction of patients with systemic lupus erythematosus, rheumatoid arthritis, and hematologic malignancies have lowered binding activity compared with normal subjects. Quantitative studies indicate the lowered activity probably arises due to a decrease in complement receptors on the respective red blood cells. The potential importance and implications of these findings are briefly discussed. | |
| 1092731 | Naproxen: corticosteroid-sparing effect in rheumatoid arthritis. | 1975 Apr | Ambulatory patients with a diagnosis of "classical" or "definite" active adult rheumatoid arthritis were selected. They had been stabilized for at least six months previously with oral administration of paramethasone acetate plus various analgesics and/or nonsteroidal anti-inflammatory agents. During an initial period of two to five weeks, the paramethasone dosage was adjusted and other medications replaced by placebo to find the minimum required to keep the patient at a level similar to the one at the beginning of the study. Subsequently, with the double-blind method, the effect of 400 mg naproxen daily was compared with placebo, making periodic and progressive reductions in the corticosteroid dosage, unknown to the patient, until a tolerable minimum was found. The average total observation time was 14 weeks. Results obtained in the first 28 patients showed an average reduction of 57 per cent in paramethasone dose for the group treated with naproxen, versus 21 per cent for the control group. One patient experienced euphoria which could possibly have been related to the test drug. It is concluded that naproxen possesses a significant corticosteroid-sparing effect with negligible toxicity. | |
| 6941688 | Plasma exchange (plasmapheresis). | 1980 | Plasma exchange (plasmapheresis), whereby 1-4 litres of patients' plasma are exchanged for a plasma substitute, has a therapeutic appeal dating back to medieval times. This blunderbuss therapy, removing as it does inflammatory mediators such as fibrin split products and complement breakdown products, immune complexes, antibodies, drugs and antigens, has been most clearly shown to have therapeutic effect in antibody-mediated diseases such as Goodpastures syndrome and Myasthenia Gravis. In chronic rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), claims for improvement have, in the main, been based on insufficient data. More recently, a number of small, uncontrolled trials have suggested that the vasculitis and arthritis of these two diseases is improved by plasmapheresis. Of clinical interest has been the repeated observation that whereas improvement in antibody titres (e.g. DNA antibodies) is transient, clinical improvement, and a lowering of immune complex titres often last for days or even weeks. A recent observation may explain, in part, this finding. Reticulo-endothelial (RES) function, as measured by disappearance rates of heat-damaged red blood cells, is frequently impaired in SLE and RA. Plasmapheresis appears to result in improved RES function, possibly by a 'desaturating' effect on circulating and RES-bound immune complexes. | |
| 6649935 | [Results of radiosynoviorthesis with yttrium 90 in chronic synovitis: a long-term prospect | 1983 Sep | The purpose of the presented study was to investigate, whether the results of radiosynovectomy were dependent on different characteristics of the chronic synovitis. In our unit, from October 1978 to April 1981 193 joints--174 knee joints and 19 shoulder joints--of 107 patients underwent radiosynoviorthesis. 93 patients (169 joints) suffered from rheumatoid arthritis of different ARA-stages (I = 16, II = 31, III = 27, IV = 19; 67 seropositive, 26 seronegative), 14 patients with 24 treated joints had chronic synovitis other than rheumatoid arthritis. Only joints with chronic synovitis in the local stages I and II were treated if they did not respond to medical therapy and intraarticular applications of corticosteroids, respectively. Joints with local stage III and IV, respectively, with instability or with a secondary osteoarthrosis were excluded from radiosynovectomy. Every six months the patients were reinvestigated, and pain, swelling, mobility, stability of the joint, frequency of effusions and intraarticular steroid applications were assessed as well as the overall activity of the disease, SR, hemoglobin and effectivity of medical treatment. The overall result was good in 60% of cases after 6 and 12 months, respectively, in 54% of cases after 2 years and in 50% of cases after 3 years, it was fair in about 35% of cases. The results of 20 repeated radiosynovectomies were comparable. The frequency of joint effusions and of necessary intraarticular corticosteroid injections was significantly reduced even in patients showing a "poor" result of synoviorthesis.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 6499511 | A double-blind comparison of meptazinol versus placebo in chronic rheumatoid arthritis and | 1984 | A double-blind, placebo-controlled, between-patient evaluation of the analgesic properties of oral meptazinol was carried out in 60 patients suffering from chronic pain due to rheumatoid arthritis and osteoarthritis. Patients were allocated, at random, to receive either 200 mg meptazinol every 3 to 6 hours as required or identical matching placebo for a total period of 72 hours. Data from 57 patients (30 on meptazinol, 27 on placebo) were suitable for analysis. Pain intensity in five major categories was assessed using a 4-point verbal rating scale by a clinician before the first dose and at the end of the trial period. Patients performed a self-assessment of pain prior to taking the first dose and subsequently at 2,4,24, 48 and 72 hours using 100 mm visual analogue scales and verbal rating scales. The clinician-rated pain scores showed no significant difference between the two groups in initial pain intensity. After 72-hours' treatment , there was a significant (p less than l.01) reduction in pain intensity after 2 hours which was maintained throughout the trial period. There was no significant reduction in pain intensity inpatients taking placebo. Visual analogue scale scores and pain intensity difference scores showed significantly (p less than 0.01) greater reduction in pain intensity at all time points in the meptazinol- treated patients.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 6813482 | Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospecti | 1982 Jul | One hundred and twelve patients with classical or definite rheumatoid arthritis (RA) were randomly assigned to receive either sodium aurothiomalate (GSTM) or auranofin (AF). Monthly clinical assessments (morning stiffness, grip strength, articular index, pain, quality of life) and concurrent hematological, biochemical, and urine studies were performed to monitor the efficacy/toxicity (E/T) ratio. Ninety-two patients have completed 3 months; 65, 6 months; 47, 9 months; and 30, 12 months. The groups were numerically balanced at each time period. Analysis of the 0-6 month period suggests that both drugs were equally and significantly beneficial after 3 months and that this was maintained at 6 months. Toxicity was as frequent in both groups but more serious in the GSTM group. The main side effects were gastrointestinal (diarrhea) in the AF group and mucocutaneous in the GSTM group. Half of the withdrawals (14 in each group) were because of side effects in the GSTM group and for inadequate therapeutic efficacy in the AF group. This study suggests that after 6 months of treatment the E/T ratio of AF is greater than or equal to that of GSTM. These conclusions will need to be confirmed during the ongoing longer observation period. A significant clinical difference between the 2 drugs is that in a given patient treated with GSTM, the onset of toxicity coincides with a good therapeutic effect. This relationship does not appear to exist during AF treatment. | |
| 6732399 | 'Hypocryoglobulins'. Enhanced cryoprecipitation from hypotonic serum in patients with vasc | 1984 Jul | Three patients with cutaneous vasculitis and one patient with digital gangrene had a negative or equivocal test for cryoglobulins but a positive result in a modified assay for cryoproteins ( hypocryoglobulins [ HGs ]) in which serum is rendered hypotonic by dilution with an equal volume of distilled water before incubation in the cold. Each cryoprecipitate contained a mixture of immunoglobulins, and in two instances, a monoclonal component was demonstrated. Rheumatoid factor activity was found in two precipitates. All four patients improved with plasmapheresis, and two subsequently responded to alkylating agents. Seven patients with conventional cryoglobulins had precipitation from diluted serum as well, but none had a substantial increase in precipitation in the HG assay. Only two of five patients with seropositive rheumatoid arthritis had abnormal levels of HG. Hypocryoglobulins are a new category of abnormally insoluble serum proteins, probably closely related to conventional cryoglobulins, which are readily detected in a simple precipitation assay. | |
| 685513 | [Effect of cyclophosphamide (Endoxan) on experimental arthritis in rabbits]. | 1978 May | The experimental investigation is divided into 3 parts: Firstly, it was assessed that cyclophosphamide (Cp) in different dosages was well tolerated locally when injected into the knee joint of normal rabbits as compared to saline controls on the basis of histology and cell count determination of the injected joints. In a second series of experiments a hyperimmune arthritis (HIA) was produced in rabbits by systemic administration of albumin, complete Freund's adjuvant and intraarticular stimulus by ovalbumin. Histological examination of synovial membranes reveal alterations similar to those of human rheumatoid arthritis on the 7th day after stimulus. Further experiments were aimed at assessing if Cp exerted an inhibitory effect on the 7 day old HIA. Cp in a dosage of 10 mg has been applied intraarticularly in various intervals prior, simultaneously and after the elicitation of HIA. It could be demonstrated that Cp led to a reduction of the number of lymphocytes, plasma cells and fibroblasts in the synovial membrane, the inhibitory effect on fibroblasts was bound to its administration around the point of HIA elicitation, an even stronger inhibition of lymphocytes and plasma-cells was only to be expected when Cp was applied 48 hours after ovalbumin challenge. Unwanted reactions in the course of Cp administration such as superficial and deep necrosis as well as damage of blood vessels in the synovial membrane combined with minor inhibition of lymphocytes and plasma cells were encountered when Cp was injected 120 hours after HIA elicitation. These new experimental results lead to the conclusion that efficacy and unwanted reactions during Cp administration are related to a local activation of the substance in the inflammatory milieu of HIA. Furthermore we were able to demonstrate that even the sole application of Cp if injected shortly before immigration of lymphocytes into the synovial tissue led to a marked suppression of almost all histological parameters of HIA. Our experimental findings strongly support the importance of lymphocytes and plasma cells being inactivated for the successful treatment of adult rheumatoid arthritis. They grow to consider the formation of necrosis and damage of blood vessels as sequelae of too fast a local activation of Cp in the inflammatory tissue. | |
| 60087 | Attempts to identify viruses in rheumatoid synovial cells. | 1976 Apr | Synovial fibroblast cell strains derived from the synovial membranes of 7 patients with rheumatoid arthritis were examined for the presence of viruses, in particular leucoviruses. Seven similar synovial strains derived from patients with other arthritic conditions were used as a control group. Evidence of the presence of a virus or a viral genome was looked for by several methods of induction followed by 3H-uridine labelling of the cultures. In addition, the culture supernatant, after induction and after the synovial strains had been co-cultivated with a variety of cell lines from several species, was assayed for the presence of viral RNA-dependent DNA polymerase activity. The DNA-polymerase activity of the synovial cells themselves was also determined. No evidence was found by any of these techniques to indicate the presence of virus or viral information within the synovial fibroblasts. | |
| 2411230 | Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in | 1985 Jul | Sera from patients with rheumatoid arthritis (RA), patients with infectious mononucleosis (IM), and blood donors were tested by indirect immunofluorescence for the presence of antikeratin antibody (AKA), antibody to cytoskeletal intermediate filaments of prekeratin or vimentin type (AIFA) and antiperinuclear factor (APF). In 81.9% of the RA sera and 92.5% of the IM sera AIFA of IgM class was found at titres up to and in some cases exceeding 1/160. In blood donors the incidence of AIFA was 26%, at titres not exceeding 1/20. AKA and APF, always of IgG class, were found in 54.2% and 73.6% of rheumatoid sera. A weak correlation was found in RA between the incidence of AIFA and APF. AKA was not present in either IM or blood donor sera, and APF was found in only 2.5% and 3.2% of IM or blood donors respectively. | |
| 6966813 | [Quantitative bone scintigraphy in the study of the sacroiliac joint in chronic inflammato | 1980 Apr | Scintillation counting of the sacro-iliac bones using technetium pyrophosphate or diphosphate is a simple examination without danger. The uptake opposite each sacro-iliac bone is assessed by reference to that of the lumbar spine visible on the film. A study of a control group of 81 subjects permits one to determine the existence of variations in relation to age: the fixation is high in subjects under the age of 20 years and reduced in adults aged over 50 years. The 44 controls from 20 to 50 years, permit one to retain as reference value, the ratio 1.14 for the right sarco-iliac bone and 1.11 for the left sarco-iliac bone with a confidence interval of 0.13. There was noted a significantly high uptake during arthritis. Whether this was the axial form (40 cases) or the peripheral from (7 cases) and during Reiter's syndrome (15 cases). This hyperfixation was more frequent and more important when the sacro-iliac involvements (whether accompanied or not by radiological signs) were the cause of inflammatory pain. Increased uptake was also noted during other forms of chronic inflammatory rheumatism: rheumatoid arthritis (10 cases). Chronic inflammatory rheumatism (unclassifiable) 20 cases. It thus seems that one may retain in many cases the existence of sacro-iliac inflammatory changes without the latter being necessarily accompanied by clinical or radiological signs. The discovery of hyperfixation of the sacro-iliacs during chronic inflammatory rheumatism is further evidence in favour of the diagnosis of sacro-iliac arthritis but should be interpretated in the light of the general context. | |
| 6725344 | The long-term results of Stanmore total knee replacements. | 1984 May | Between 1969 and 1971 20 prototypes of the Stanmore total knee prosthesis were used to replace severely arthritic knees in 18 patients. Seven patients died before the final follow-up and one had to have her leg amputated because of deep infection; in none of these patients had the prosthesis become loose. Ten patients (11 knees) were reviewed at least 10 years after operation. There was no significant clinical deterioration in 7 of these 11 surviving knees when the results at one year were compared with those at 10 years. | |
| 6885387 | Indications for total surface replacement of the hip joint. | 1983 Mar | The authors briefly review the literature on total surface replacement of the hip, in particular, the indications, complications and results so far obtained. Their personal experience began five years ago with Wagner's prosthesis, and they report 20 cases operated on and followed up for 3-5 years. The results were favourable. In their view, this prosthesis is indicated in selected cases, especially in subjects aged less than 50 years, as an alternative to arthrodesis, cervico-epiphyseal resection, or total joint replacement, provided that the anatomical condition of the femoral head is satisfactory. | |
| 7190198 | [Detection of complement-binding immune complexes by means of 51Cr-labeled indicator cells | 1980 May 2 | A new radioimmunoassay for the detection of complement-binding immune complexes is described. The method is based on the ability of the complexes to bind added guinea pig complement (Clq-Component) so that is not available for lysis of 51Cr-labeled chicken red blood cells in a haemolytic system. Sera from 45 patients with malignant tumours, 20 patients with nonmalignant diseases were studied for the presence of circulating immune complexes. The complement-binding capacity of the sera of patients with significantly greater than that of control sera. |